New from Hobart and our companies

Results from EPD’s DURABLE-I clinical trial, whose principal investigator is Professor Evgeny A Pokushalov, were presented for the first time at the 2017 AF Symposium by Professor Karl-Heinz Kuck, Head of the Department of Cardiology at the Asklepios Klinik in Hamburg, Germany. The presentation, “DURABLE-I Study: Real-time gap detection during AF ablation using dielectric sensing”, […]

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study

Orangeburg, New York. August 8, 2017

Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm continued access evaluation of the company’s Cardiac Contractility Modulation (CCM) device. Impulse Dynamics’ proprietary CCM technology delivers non-excitatory electric pulses to the cardiac muscle, with the potential for improved exercise capacity and quality of life.

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017

Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]

Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are symptomatic despite appropriate medical therapy…

Data from a prospective multicenter, randomized, open, blinded end-point, exploratory clinical trial examining robotic therapy combined with standard upper extremity therapy in patients recovering form stroke was published in the March issue of the American Heart Association’s Stroke journal…

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, Germany, May 11, 2017

Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round…

Going red to raise awareness of heart disease in women

Spinal injury patient learns to walk again with Motorika’s ReoAmbulator

October 18, 2016

Motorika’s pioneering lower limb robotic rehabilitation system, the ReoAmbulator, is already changing the lives of patients in the US suffering from neurological and orthopedic disorders. NHC HealthCare, Clinton recently reported its successful experience with the first system to be installed in the US…

Molecular Dynamics has successfully completed the first phase of a clinical trial to evaluate the Valiance X12 whole-body Cadmium Zinc Telluride (CZT) based digital SPECT/CT prototype with promising results. The study, conducted at the Chaim Sheba Medical Center in Israel, was designed to assess the image quality and diagnostic performance of the Valiance X12 and demonstrated improved image resolution and contrast.

Renal Dynamics has successfully treated the first patient in its TREAT-HTN prospective, post-marketing multi-center European clinical study to evaluate the safety and efficacy of its third-generation Renal Denervation (ReDy™) System.

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study

Orangeburg, New York. August 8, 2017

Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm continued access evaluation of the company’s Cardiac Contractility Modulation (CCM) device. Impulse Dynamics’ proprietary CCM technology delivers non-excitatory electric pulses to the cardiac muscle, with the potential for improved exercise capacity and quality of life.

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, Germany, May 11, 2017

Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round…

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017

Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]

Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are symptomatic despite appropriate medical therapy…

Spinal injury patient learns to walk again with Motorika’s ReoAmbulator

October 18, 2016

Motorika’s pioneering lower limb robotic rehabilitation system, the ReoAmbulator, is already changing the lives of patients in the US suffering from neurological and orthopedic disorders. NHC HealthCare, Clinton recently reported its successful experience with the first system to be installed in the US…

Molecular Dynamics has successfully completed the first phase of a clinical trial to evaluate the Valiance X12 whole-body Cadmium Zinc Telluride (CZT) based digital SPECT/CT prototype with promising results. The study, conducted at the Chaim Sheba Medical Center in Israel, was designed to assess the image quality and diagnostic performance of the Valiance X12 and demonstrated improved image resolution and contrast.

Data from a prospective multicenter, randomized, open, blinded end-point, exploratory clinical trial examining robotic therapy combined with standard upper extremity therapy in patients recovering form stroke was published in the March issue of the American Heart Association’s Stroke journal…

Renal Dynamics has successfully treated the first patient in its TREAT-HTN prospective, post-marketing multi-center European clinical study to evaluate the safety and efficacy of its third-generation Renal Denervation (ReDy™) System.

About Hobart Group

The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia. For more information, visit www.Hobart-Group.com.

Media kit

Journalists and reporters are welcome to use the following materials related to Hobart Group